• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Clinical efficacy of convalescent plasma therapy on treating COVID-19 patients: Evidence from matched study and a meta-analysis.

作者信息

Jiang Weijun, Li Weiwei, Xiong Lei, Wu Qiuyue, Wu Jian, He Bangshun, Shen Jiawei, Pang Rongrong, Luo Tao, Guo Yanju, Yang Yang, Han Ying, Dai Wei, Zhu Peiran, Xia Xinyi

机构信息

COVID-19 Research Center, Institute of Laboratory Medicine, Jinling Hospital, Nanjing University School of Medicine, The First School of Clinical Medicine, Southern Medical University, Nanjing, China.

General Clinical Research Center, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.

出版信息

Clin Transl Med. 2020 Dec;10(8):e259. doi: 10.1002/ctm2.259.

DOI:10.1002/ctm2.259
PMID:33377664
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7752155/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a742/7752155/ad3205422ea4/CTM2-10-e259-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a742/7752155/cc847a27905c/CTM2-10-e259-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a742/7752155/ad3205422ea4/CTM2-10-e259-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a742/7752155/cc847a27905c/CTM2-10-e259-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a742/7752155/ad3205422ea4/CTM2-10-e259-g002.jpg

相似文献

1
Clinical efficacy of convalescent plasma therapy on treating COVID-19 patients: Evidence from matched study and a meta-analysis.恢复期血浆疗法治疗新冠肺炎患者的临床疗效：来自配对研究和荟萃分析的证据。
Clin Transl Med. 2020 Dec;10(8):e259. doi: 10.1002/ctm2.259.
2
A 63-Year-Old Woman with SARS-CoV-2 Infection, Who Developed Severe COVID-19 Pneumonia and Was Supported with Convalescent Plasma Therapy.一名63岁感染严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的女性，她发展为重症冠状病毒病2019（COVID-19）肺炎并接受了恢复期血浆治疗。
Am J Case Rep. 2020 Sep 29;21:e927662. doi: 10.12659/AJCR.927662.
3
Convalescent plasma to treat coronavirus disease 2019 (COVID-19): considerations for clinical trial design.恢复期血浆治疗 2019 冠状病毒病（COVID-19）：临床试验设计的考虑因素。
Transfusion. 2020 Jun;60(6):1123-1127. doi: 10.1111/trf.15843. Epub 2020 May 12.
4
[Application of convalescent plasma therapy on novel coronavirus infection].[康复期血浆疗法在新型冠状病毒感染中的应用]
Zhonghua Jie He He Hu Xi Za Zhi. 2020 May 12;43(5):409-413. doi: 10.3760/cma.j.cn112147-20200304-00237.
5
Convalescent plasma therapy and remdesivir duo successfully salvaged an early liver transplant recipient with severe COVID-19 pneumonia.恢复期血浆疗法联合瑞德西韦成功挽救了一名患有重症COVID-19肺炎的早期肝移植受者。
Ann Hepatobiliary Pancreat Surg. 2020 Nov 30;24(4):526-532. doi: 10.14701/ahbps.2020.24.4.526.
6
Novel Antiviral Strategies in the Treatment of COVID-19: A Review.治疗新冠肺炎的新型抗病毒策略：综述
Microorganisms. 2020 Aug 20;8(9):1259. doi: 10.3390/microorganisms8091259.
7
[Effect of convalescent plasma and immunoglobulin on patients with severe acute respiratory syndrome: a systematic review].[康复期血浆及免疫球蛋白对重症急性呼吸综合征患者的影响：一项系统评价]
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2020 Apr;32(4):435-438. doi: 10.3760/cma.j.cn121430-20200326-00240.

引用本文的文献

1
Hypoglycemia and Alzheimer Disease Risk: The Possible Role of Dasiglucagon.低血糖与阿尔茨海默病风险：地特胰岛素的可能作用。
Cell Mol Neurobiol. 2024 Jul 8;44(1):55. doi: 10.1007/s10571-024-01489-y.
2
Rates Among Hospitalized Patients With COVID-19 Treated With Convalescent Plasma: A Systematic Review and Meta-Analysis.接受恢复期血浆治疗的新冠肺炎住院患者的发生率：一项系统评价和荟萃分析。
Mayo Clin Proc Innov Qual Outcomes. 2023 Oct 10;7(5):499-513. doi: 10.1016/j.mayocpiqo.2023.09.001. eCollection 2023 Oct.
3
COVID-19 Convalescent Plasma and Clinical Trials: Understanding Conflicting Outcomes.

本文引用的文献

1
Mortality reduction in 46 severe Covid-19 patients treated with hyperimmune plasma. A proof of concept single arm multicenter trial.46 例重症 COVID-19 患者接受免疫血浆治疗后的死亡率降低：一项概念验证性单臂多中心试验。
Haematologica. 2020 Dec 1;105(12):2834-2840. doi: 10.3324/haematol.2020.261784.
2
Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial).恢复期血浆治疗印度成人中度 COVID-19 的管理：开放标签 II 期多中心随机对照试验（PLACID 试验）。
BMJ. 2020 Oct 22;371:m3939. doi: 10.1136/bmj.m3939.
3
The therapeutic potential of convalescent plasma therapy on treating critically-ill COVID-19 patients residing in respiratory care units in hospitals in Baghdad, Iraq.
COVID-19 恢复期血浆与临床试验：解读相悖的结果
Clin Microbiol Rev. 2022 Sep 21;35(3):e0020021. doi: 10.1128/cmr.00200-21. Epub 2022 Mar 9.
4
Association between tocilizumab treatment and clinical outcomes of COVID-19 patients: a systematic review and meta-analysis.托珠单抗治疗与 COVID-19 患者临床结局的相关性：系统评价和荟萃分析。
Aging (Albany NY). 2022 Jan 17;14(2):557-571. doi: 10.18632/aging.203834.
5
How to translate the knowledge of COVID-19 into the prevention of Omicron variants.如何将新冠病毒的知识转化为对奥密克戎变异株的预防。
Clin Transl Med. 2021 Dec;11(12):e680. doi: 10.1002/ctm2.680.
6
The Effectiveness of Convalescent Plasma for the Treatment of Novel Corona Virus Disease 2019: A Systematic Review and Meta-Analysis.康复期血浆治疗2019年新型冠状病毒病的有效性：一项系统评价和荟萃分析。
Front Med (Lausanne). 2021 Sep 27;8:641429. doi: 10.3389/fmed.2021.641429. eCollection 2021.
7
Efficacy and secondary infection risk of tocilizumab, sarilumab and anakinra in COVID-19 patients: A systematic review and meta-analysis.托珠单抗、沙利鲁单抗和阿那白滞素治疗 COVID-19 患者的疗效和二次感染风险：系统评价和荟萃分析。
Rev Med Virol. 2022 May;32(3):e2295. doi: 10.1002/rmv.2295. Epub 2021 Sep 24.
8
Convalescent plasma associates with reduced mortality and improved clinical trajectory in patients hospitalized with COVID-19.恢复期血浆与 COVID-19 住院患者的死亡率降低和临床病程改善相关。
J Clin Invest. 2021 Oct 15;131(20). doi: 10.1172/JCI151788.
9
Efficacy and Safety of Tocilizumab Treatment COVID-19 Patients: A Case-Control Study and Meta-Analysis.托珠单抗治疗新冠病毒肺炎患者的疗效与安全性：一项病例对照研究及荟萃分析
Infect Dis Ther. 2021 Sep;10(3):1677-1698. doi: 10.1007/s40121-021-00483-x. Epub 2021 Jul 9.
10
Contemporary narrative review of treatment options for COVID-19.当代关于 COVID-19 治疗方法的叙事性综述。
Respirology. 2021 Aug;26(8):745-767. doi: 10.1111/resp.14106. Epub 2021 Jul 8.
康复期血浆疗法对治疗伊拉克巴格达医院呼吸监护病房中危重新冠肺炎患者的治疗潜力。
Infez Med. 2020 Sep 1;28(3):357-366.
4
Clinical efficacy of convalescent plasma for treatment of COVID-19 infections: Results of a multicenter clinical study.康复期血浆治疗新型冠状病毒肺炎感染的临床疗效：一项多中心临床研究的结果
Transfus Apher Sci. 2020 Oct;59(5):102875. doi: 10.1016/j.transci.2020.102875. Epub 2020 Jul 15.
5
Use of convalescent plasma in hospitalized patients with COVID-19: case series.COVID-19 住院患者使用恢复期血浆：病例系列。
Blood. 2020 Aug 6;136(6):759-762. doi: 10.1182/blood.2020006964.
6
Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial.恢复期血浆疗法对重症和危及生命的 COVID-19 患者临床改善时间的影响：一项随机临床试验。
JAMA. 2020 Aug 4;324(5):460-470. doi: 10.1001/jama.2020.10044.
7
Clinical Characteristics of Coronavirus Disease 2019 in China.《中国 2019 年冠状病毒病临床特征》
N Engl J Med. 2020 Apr 30;382(18):1708-1720. doi: 10.1056/NEJMoa2002032. Epub 2020 Feb 28.
8
The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis.恢复期血浆和高效免疫球蛋白治疗病毒性病因严重急性呼吸道感染的有效性：系统评价与探索性Meta分析
J Infect Dis. 2015 Jan 1;211(1):80-90. doi: 10.1093/infdis/jiu396. Epub 2014 Jul 16.